Clinical Trials
52 trialsSapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations
National Cancer Institute (NCI)
Bristol Bladder Trial
University Hospitals Bristol and Weston NHS Foundation Trust
Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)
Incyte Corporation
Optimus
Incyte Corporation
PRESERVE3
G1 Therapeutics, Inc.
Immunotherapy With or Without Radiation Therapy for Metastatic Urothelial Cancer
National Cancer Institute (NCI)
A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201)
Incyte Corporation
Study of Bacillus Calmette-Guerin (BCG) Combined With PANVAC Versus BCG Alone in Adults With High Grade Non-Muscle Invasive Bladder Cancer Who Failed At Least 1 Course of BCG
National Institutes of Health Clinical Center (CC)
Cabazitaxel in Patients With Urothelial Carcinoma Who Have Disease Progression Following Platinum-Based Chemotherapy
Thomas Jefferson University
AUREA
Spanish Oncology Genito-Urinary Group
PEGASUS
European Association of Urology Research Foundation
Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial Carcinoma
Case Comprehensive Cancer Center
ABLE
University of Michigan Rogel Cancer Center
Atezolizumab With Bevacizumab in Previously Untreated Metastatic/Unresectable Urothelial Cancer
Hoosier Cancer Research Network
PemCab
University of Utah
Neutron Radiation Therapy and Pembrolizumab in Treating Participants With Advanced Urothelial Carcinoma
University of Washington
Trial of Mitomycin C During Nephroureterectomy for Urothelial Carcinoma
University of Florida
EV-201
Astellas Pharma Inc
Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma
National Cancer Institute (NCI)
Trial of Tremelimumab in Patients With Previously Treated Metastatic Urothelial Cancer
Hoosier Cancer Research Network
Neoadjuvant Atezolizumab in Localized Bladder Cancer
University of California, San Francisco
Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations
SCRI Development Innovations, LLC
Nab-paclitaxel Plus Gemcitabine as First-line Therapy for Cisplatin-ineligible or Cisplatin-incurable Advanced Urothelial Carcinoma
SCRI Development Innovations, LLC
First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
Hoosier Cancer Research Network
Trial of Atezolizumab Plus Chemotherapy After Progression on PD-1 or PD-L1 in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
Hoosier Cancer Research Network
A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma
Mirati Therapeutics Inc.
Evaluation of Oxaliplatin and Gemcitabine in Patients With Metastatic Bladder Cancer
University of California, Irvine
A Study to Evaluate ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer
OncoNano Medicine, Inc.
ATLAS
pharmaand GmbH
PIVOT-10
Nektar Therapeutics
Paclitaxel and Pembrolizumab in Treating Patients With Refractory Metastatic Urothelial Cancer
Wake Forest University Health Sciences
Everolimus (RAD001) in Metastatic Transitional Cell Carcinoma of the Urothelium
Memorial Sloan Kettering Cancer Center
Cabozantinib for Advanced Urothelial Cancer
National Institutes of Health Clinical Center (CC)
Testing the PD-1 Inhibitor Pembrolizumab as Maintenance Therapy After Initial Chemotherapy in Metastatic Bladder Cancer
Hoosier Cancer Research Network
OPTIMA II
UroGen Pharma Ltd.
Neoadjuvant Immunotherapy in Brain Metastases
Duke University
First-Line Gemcitabine, Cisplatin + Ipilimumab for Metastatic Urothelial Carcinoma
Hoosier Cancer Research Network
Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer
Hoosier Cancer Research Network
Anti-PD(L)1 and SBRT in the Treatment of Advanced, Platinum-Refractory Urothelial Carcinoma
University of Michigan Rogel Cancer Center
A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary Cancers
Weill Medical College of Cornell University
Pemetrexed Disodium in Treating Patients With Previously Treated Metastatic Urothelial Cancer
M.D. Anderson Cancer Center
Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma
National Institutes of Health Clinical Center (CC)
Study of Pralatrexate to Treat Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder
Acrotech Biopharma Inc.
KEYNOTE143
Acerta Pharma BV
A Study of MOXR0916 in Combination With Atezolizumab Versus Atezolizumab Alone in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-Based Therapy
Genentech, Inc.
Phase II Trial of Palbociclib in Patients With Metastatic Urothelial Cancer After Failure of First-Line Chemotherapy
UNC Lineberger Comprehensive Cancer Center
Randomized Study of Docetaxel +/- Vandetanib in Metastatic TCC
Dana-Farber Cancer Institute
Trial of Adjuvant Sutent for Patients With High Risk Urothelial Carcinoma After Neoadjuvant Chemotherapy and Cystectomy
University of Michigan
DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
Dendreon
TRC105 in Adults With Advanced/Metastatic Urothelial Carcinoma
National Institutes of Health Clinical Center (CC)